Philipp Harter

Active 2006–2025

159
Papers
25,849
Citations
76
h-index
149
i10-index

Citations

Citations per year for Philipp Harter1998: 2 citations2008: 4 citations2009: 6 citations2010: 26 citations2011: 38 citations2012: 56 citations2013: 72 citations2014: 90 citations2015: 141 citations2016: 197 citations2017: 250 citations2018: 227 citations2019: 928 citations2020: 1,132 citations2021: 1,055 citations2022: 852 citations2023: 765 citations2024: 1,391 citations2025: 694 citations2026: 16 citations1999–2007: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,770 citing papers, 17.8% of this breakdownChina: 905 citing papers, 9.1% of this breakdownUnited Kingdom: 763 citing papers, 7.6% of this breakdownItaly: 720 citing papers, 7.2% of this breakdownGermany: 525 citing papers, 5.3% of this breakdownFrance: 469 citing papers, 4.7% of this breakdownSpain: 412 citing papers, 4.1% of this breakdownCanada: 396 citing papers, 4% of this breakdownJapan: 315 citing papers, 3.2% of this breakdownAustralia: 306 citing papers, 3.1% of this breakdownNetherlands: 278 citing papers, 2.8% of this breakdownBelgium: 242 citing papers, 2.4% of this breakdown
0%17.8%Other 28.7%

Fields

  • Medicine75.2%
  • Biochemistry, Genetics and Molecular Biology17.5%
  • Immunology and Microbiology2.1%
  • Computer Science0.7%
  • Neuroscience0.7%
  • Engineering0.6%
  • Other3.2%

Topics

  • Ovarian cancer diagnosis and treatment14.2%
  • PARP inhibition in cancer therapy11%
  • Endometrial and Cervical Cancer Treatments5.1%
  • DNA Repair Mechanisms3.5%
  • BRCA gene mutations in cancer3.2%
  • Intraperitoneal and Appendiceal Malignancies2.8%
  • Other60.2%

Coauthors

All papers

Open in search
  1. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 2,040

  2. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano, Kian Behbakht, Susan A. Davidson and 21 more - The Lancet Oncology 2017 cited by 1,863

  3. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , , - Annals of Oncology 2022 cited by 638

  4. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 372

  5. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: , , , , , , , , , , - Annals of Oncology 2023 cited by 388

  6. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 cited by 394

  7. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 cited by 339

  8. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2012 cited by 1,891

  9. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sophie Abadie‐Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria-Pilar Barretina-Ginesta, Marco Johannes Battista, Charlotte Béllier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Cláudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus C. Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García García, Elena Geuna, Eva Guerra, Lars Hanker, Anne‐Claire Hardy‐Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, M. Koegel, Anthoula Koliadi, Jean‐Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Shin Nishio, Ana Oaknin, Michaela Onstad, Beatriz Pardo, José Alejandro Pérez Fidalgo, Carmela Pisano, Andrés Poveda, Julia Caroline Radosa and 21 more - The Lancet 2023 cited by 209

  10. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Giovanni Scambia, Maria Ornella Nicoletto, Fiona Nussey, Andrew R. Clamp, Richard T. Penson, Amit M. Oza, A. Poveda Velasco, Manuel Rodrigues, Jean‐Pierre Lotz, Frédèric Selle, Isabelle Ray‐Coquard, Diane Provencher, Aleix Prat Aparicio, Laura Vidal Boixader, Clare L. Scott, Kenji Tamura, Mayu Yunokawa, Alla Lisyanskaya, Jacques Médioni, Nicolas Pécuchet, Coraline Dubot, Thibault De La Motte Rouge, Marie‐Christine Kaminsky, B. Weber, Alain Lortholary, Christine Parkinson, Jonathan A. Ledermann, Sarah Williams, Susana Banerjee, Jonathan A. Cosin, James Hoffman, Richard T. Penson, Marie Plante, Allan Covens, Gabe S. Sonke, Florence Joly, Anne Floquet, Susana Banerjee, Holger W. Hirte, Amnon Amit, Tjoung-Won Park-Simon, Koji Matsumoto, Sergei Tjulandin, Jae‐Hoon Kim, Laurence Gladieff, Roberto Sabbatini, David M. O’Malley, Patrick Timmins, Daniel Kredentser, Nuria Laínez Milagro, M.P. Barretina Ginesta, Ariadna Tibau Martorell, Alfonso Gómez de Liaño, Belén Ojeda González, Linda Mileshkin, Masaki Mandai, Ingrid Boere, Petronella B. Ottevanger, Joo‐Hyun Nam, Elias Abdo Filho, Salima Hamizi, Francesco Cognetti, David Warshal, Elizabeth Dickson-Michelson, Scott Kamelle, Nathalie D. McKenzie, Gustavo C. Rodriguez, Deborah K. Armstrong, Eva Chalas, Paul Celano and 23 more - The Lancet Oncology 2021 cited by 416

  11. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials

    Authors: , , , , , - Cancer 2009 cited by 1,614

  12. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2014 cited by 1,443

  13. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , José Alejandro Pérez Fidalgo, Sandro Pignata, Pedro T. Ramírez, Isabelle Ray‐Coquard, Ignacio Romero, Giovanni Scambia, Jalid Sehouli, Ronnie Shapira‐Frommer, Sudha Sundar, David S.P. Tan, Çağatay Taşkıran, Willemien J. van Driel, Ignace Vergote, François Planchamp, Cristiana Sessa, Anna Fagotti - Annals of Oncology 2024 cited by 284

  14. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 600

  15. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 cited by 315

  16. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susana Banerjee, Massimo Barberis, M.P. Barretina Ginesta, J.F. Baurain, Margherita Bignami, Line Bjørge, Paweł Blecharz, Ilan Bruchim, ME Capilna, Nicoletta Cerana, Americo Cicchetti, Dearbhaile Catherine Collins, Nicole Concin, Maurizio D’Incalci, Brittany A. Davidson, Thibault De La Motte Rouge, Pierandrea De Iaco, Fuat Demirkıran, Hannelore Denys, Thilo Doerk, Anne Dørum, Annamaria Ferrero, Alejandro Perez Fidalgo, Maurizio Genuardi, Laurence Gladieff, Rosalind Glasspool, Christoph Grimm, Murat Gültekin, E. Hahnen, Annette Hasenburg, Alinta Hegmane, Viola Heinzelmann, Estrid Høgdall, Ramūnas Janavičius, Sonata Jarmalaitė, Roshni Kalachand, Radka Kaneva, Saadettin Kılıçkap, Roman Kocián, D. Kolencik, Rebecca Kristeleit, Anna Kryzhanivska, Alexandra Léary, Birthe Lemley, Marjolijn J. L. Ligtenberg, José Antonio López‐Guerrero, Christopher J. Lord, E. Åvall‐Lundqvist, Johanna Mäenpää, Sven Mahner, Frederik Marmé, Christian Marth, Iain A. McNeish, Sabine Merkelbach‐Bruse, Marian J.E. Mourits, Nicola Normanno, Ana Oaknin, Kristiina Ojamaa, C. Papdimitriou, F. Penault-Llorca, Anna Myriam Perrone, Sandro Pignata, Eli Pikarsky, Étienne Rouleau, María Jesús Rubio, Anna Sapino, Barbara Schmalfeldt, Jalid Sehouli, Roni Shapira, Karina Dahl Steffensen and 12 more - Annals of Oncology 2021 cited by 164

  17. Treatment of recurrent ovarian cancer

    Authors: , , , , - Annals of Oncology 2017 cited by 354

  18. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jean‐Emmanuel Kurtz, Sven Ackermann, C. Anthuber, Mustafa Aydoğdu, Angelika Baldauf, Wolfgang Bauer, Dirk Behringer, Antje Belau, Alexandra Bender, Cosima Brucker, Alexander Burges, Ulrich Canzler, Trygve Daabach, Dominik Denschlag, Mustafa Deryal, Steffen Dörfel, Juliane Ebert, Ahmed El-Balat, Tanja Fehm, Susanne Maria Feidicker, Gabriele Feisel-Schwickardi, R. Felberbaum, Matthias Frank, Gerhard Gebauer, Bernd Gerber, Axel Gerhardt, Andrea Gräfe, Martin Grießhammer, Eva‐Maria Grischke, Isolde Gröll, Martina Gropp‐Meier, Dietrich Hager, Volker Hanf, Carla Hannig, Peer Hantschmann, Philipp Harter, Tanja Hauzenberger, Uwe Herwig, Martin Heubner, Carsten Hielscher, Felix Hilpert, T Hitschold, Manfred Hofmann, Christian Jackisch, Wolfgang Janni, Ludwig Kiesel, Yon‐Dschun Ko, H. Koch, Petra Krabisch, Peter Krieger, Thomas Kubin, Thorsten Kühn, Björn Lampe, P. Ledwon, Sabine Lemster, B. Lex, Clemens Liebrich, Ralf Lorenz, Hans‐Joachim Lück, Sven� Mahner, Peter Mallmann, Frederik Marmé, Werner Meier, Wolfgang Meinerz, Götz Menke, Volker Möbus, Thomas Müller, Volker Müller, Tanja Neunhöffer, Angelika Ober and 87 more - The Lancet Oncology 2020 cited by 162

  19. Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor Entities

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2022 cited by 70

  20. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase

    Authors: , , , , , , , , , , - Gynecologic Oncology 2016 cited by 230

  21. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

    Authors: , , , , , , , , , - Annals of Oncology 2012 cited by 340

  22. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO‐OVAR OP7)

    Authors: , , , , , , , , , , , , , - International Journal of Gynecological Cancer 2019 cited by 184

  23. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - International Journal of Gynecological Cancer 2023 cited by 60

  24. Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

    Authors: , , , , , , , , , , , , , , , , , , , - Gynecologic Oncology 2021 cited by 90